Efalizumab-induced pancytopenia;Pancytopénie au cours d'un traitement par efalizumab

Annales de Dermatologie et de Venereologie

Volumn 135, Issue 5, 2008, Pages 407-408

  Nosbaum, A ^a   Allombert Blaise, C ^a   Ly, A ^a   Jullien, D ^a   Faure, M ^a   Claudy, A ^a   Simon, M ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; EFALIZUMAB; METHOTREXATE; RETINOID; MONOCLONAL ANTIBODY;

ADULT; CASE REPORT; CLINICAL FEATURE; CORTICOSTEROID THERAPY; DRUG WITHDRAWAL; HUMAN; LABORATORY TEST; LETTER; MALE; PANCYTOPENIA; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; SEROLOGY; SKIN BIOPSY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; BIOPSY; CHEMICALLY INDUCED DISORDER; LYMPHOMA; MIDDLE AGED; PATHOLOGY; TESTIS TUMOR;

ANTIBODIES, MONOCLONAL; BIOPSY; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PANCYTOPENIA; TESTICULAR NEOPLASMS;

EID: 48949097719     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2007.05.005     Document Type: Letter

References (4)

1. Scheinfeld N. Efalizumab: a review of events reported during clinical trials and side effects. Expert Opin Drug Saf 5 (2006) 197-209
2. Warkentin T.E., and Kwon P. Immune thrombocytopenia associated with efalizumab therapy for psoriasis. Ann Intern Med 14 (2005) 761-763
3. Tom W.L., Miller M.D., Hurley M.Y., Suneja T., Kudva G., Leornardi C.L., et al. Efalizumab-induced auto-immune pancytopenia. Br J Dermatol 155 (2006) 1045-1047
4. Papayannopoulou T., and Brice M. Integrin expression profiles during erythroid differentiation. Blood 79 (1992) 1686-1694